益气养阴汤联合同步放化疗治疗Ⅲ期不可切非小细胞肺癌临床观察  

Clinical Observation of Yiqi Yangyin Decoction(益气养阴汤)Combined with Concurrent Chemoradiotherapy in StageⅢUnresectable Non-Small Cell Lung Cancer

作　　者：程伟[1,2] 刘永 程紫薇 翁苓苓 CHENG Wei;LIU Yong;CHENG Ziwei;WENG Lingling(Lu′an Hospital of Traditional Chinese Medicine,Lu′an 237006,Anhui,China;The Second People′s Hospital of Hefei,Hefei 230011,Anhui,China;Dahua Hospital of Xuhui District,Shanghai 200237,China;Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine,Nanjing 210012,Jiangsu,China)

机构地区：[1]六安市中医院,安徽六安237006 [2]合肥市第二人民医院,安徽合肥230011 [3]上海徐汇区大华医院,上海200237 [4]南京中医药大学附属南京中医院,江苏南京210012

出　　处：《辽宁中医杂志》2025年第3期128-131,共4页Liaoning Journal of Traditional Chinese Medicine

基　　金：国家自然科学基金青年项目(81703868);安徽省高校科研项目重点项目(2022AH050496);安徽省卫生健康科研项目一般项目(AHWJ2023A20434);安徽省中医药传承创新科研项目(2024CCCX231)。

摘　　要：目的探讨益气养阴汤联合同步放化疗(concurrent chemoradiotherapy,CCRT)治疗Ⅲ期不可切非小细胞肺癌(non-small cell lung cancer,NSCLC)的有效性及安全性。方法80例Ⅲ期不可切NSCLC患者随机分为观察组40例和对照组40例。对照组仅予CCRT,观察组予益气养阴汤联合CCRT,后予益气养阴汤维持治疗3个月。CCRT后随访3个月,观察两组患者的近期疗效和不良反应。结果两组疾病控制率分别为95.0%(38/40)和77.5%(31/40)(P<0.05)。两组治疗后血清癌胚抗原(carcinoma antigen,CEA)和血清鳞状细胞癌抗原(squamous cell carcinoma antigen,SCC)均较治疗前下降(P<0.05),且观察组较对照组下降更明显(P<0.05)。治疗后,观察组部分中医症状评分较治疗前下降(P<0.05),且低于对照组(P<0.05)。治疗后,对照组KPS评分较治疗前下降明显(P<0.05),且低于观察组(P<0.05)。治疗后,观察组任何级别胃肠道反应和骨髓抑制发生率均低于对照组(P<0.05)。结论益气养阴汤联合CCRT治疗Ⅲ期不可切NSCLC可能会增加CCRT的疗效,减轻CCRT的不良反应。Objective To evaluate the efficacy and safety of Yiqi Yangyin Decoction(益气养阴汤)combined with concurrent chemoradiotherapy(CCRT)in stage III unresectable non-small cell lung cancer(NSCLC).Methods Eighty patients with stage III unresectable NSCLC were randomly divided into treatment group(40 cases)and control group(40 cases).The treatment group was given Yiqi Yangyin Decoction combined with CCRT,followed by Yiqi Yangyin Decoction maintenance treatment for 3 months,while the control group was given CCRT only.The two groups were followed up for 3 months after CCRT to observe the short-term efficacy and toxicity.Results The disease control rates of the two groups were 95.0%(38/40)and 77.5%(31/40),respectively(P<0.05).The serum carcinoma antigen(CEA)and serum squamous cell carcinoma antigen(SCC)of the two groups decreased significantly,and the decrease of the treatment group was more obvious compared to that of the control group(P<0.05).The scores of some traditional Chinese medicine symptoms of post-treatment in the treatment group decreased significantly compared to those pre-treatment and post-treatment in the control group(P<0.05).The KPS score of post-treatment in the treatment group did not significantly decrease compared to that pre-treatment(P>0.05),while the KPS score of post-treatment in the control group decreased significantly compared to that pre-treatment(P<0.05).The incidence of bone marrow suppression and gastrointestinal reactions at any level in the treatment group was significantly lower than that in the control group(P<0.05).Conclusion The combination of Yiqi Yangyin Decoction and CCRT in stageⅢunresectable NSCLC may increase the efficacy of CCRT and alleviate its toxic side effects.

关 键 词：非小细胞肺癌 益气养阴汤 同步放化疗 

分 类 号：R273[医药卫生—中西医结合]